In a French hearing room, the people who know most about living with Alzheimer's disease were given five minutes. That detail comes from Lorene Gilly, head of public affairs at France Alzheimer, in a World Dementia Council roundtable record published in Alzheimer's & Dementia on 24 July 2026. Between September 2025 and May 2026, she reported, the French National Authority for Health refused early access to both lecanemab and donanemab, concluding that neither offered sufficient clinical benefit and that delivering them would place an excessive burden on health systems. France, she noted, has reimbursed no Alzheimer's medicine at all since it dropped coverage of the older symptomatic drugs in 2018. Five minutes, then a decision that shapes the next decade of a family's life. And then, mostly, quiet.
That quiet is what the Council decided to name. In its update published on 22 March 2026 in Alzheimer's & Dementia, the journal of the Alzheimer's Association, the Council set out two linked reflections: one on the ageing of the world's population and brain health, the other on how societies have responded to the arrival of treatments. It is worth being precise about what this document is. It is a commentary and a record of the Council's discussions, not a trial, not a survey, not a study with participants. Its striking passage argues that other policy priorities have historically moved when public passion and anger demanded change, and that this has been somewhat lacking in dementia. The Council calls it an "absence of anger", and suggests it may stem from how people think about ageing and dementia, and from public skepticism about the treatments themselves.
The machinery behind the gap is not mysterious, and the Council describes it without drama. Regulatory approval establishes that a treatment is safe and effective. Payers then decide, separately, whether to cover it, weighing that choice against national budgets and every other spending pressure in the system. Two gates, two different questions, two different answers. The result, the Council writes, is that access is limited in many countries, often confined to people who can pay or to places where public health systems have adopted coverage. Alzheimer Europe put numbers on that geography in a position paper announced on 8 June 2026: health technology assessment bodies in Denmark, Finland, France, the Netherlands, Spain, Sweden and the United Kingdom have recommended against covering the medicines, while Austria, Germany and Luxembourg have provisional coverage, and the drugs are available in Japan and the United States.
Britain is the clearest case of a licence that does not open a door. David Thomas, head of policy and public affairs at Alzheimer's Research UK, told the June roundtable that the UK medicines regulator licensed lecanemab and donanemab in 2024, but that market authorisation does not equal patient access; neither is reimbursed by the NHS. His list of barriers was unsentimental: limited political bandwidth for dementia, payer concerns about cost and perceived benefit, a clinical community divided over what counts as meaningful benefit, and a health service not built to deliver infusions and scans at scale. The National Institute for Health and Care Excellence, in final draft guidance published in June 2025, concluded that the benefits of the two drugs remained "too small to justify the additional cost to the NHS", citing the small effects seen in the trials, the absence of long-term evidence, and the resources that would be diverted from other treatments. Manufacturers appealed. NICE opened a further consultation on 31 March 2026, and its committee met again on 10 June 2026, according to The Pharmaceutical Journal.
For a family, this is not an abstraction about thresholds and quality-adjusted life years. These medicines are licensed for early Alzheimer's disease, which means eligibility is a window, not a permanent status; Gilly's point at the roundtable was that the window narrows every day a decision is deferred. It also means most people reading this are outside the argument entirely, because the drugs are not treatments for vascular dementia, Lewy body dementia, frontotemporal dementia or the many rarer forms. What the roundtable converged on was a change of tactics rather than a change of evidence: participants agreed that advocacy needs to become more political, that evidence-based arguments have been necessary but not sufficient, and that decision-makers need to feel a cost to inaction. They also argued for reframing what a meaningful benefit is, in the terms people actually use, more time to travel, more time at the things that make a life.
None of which answers the Council's own question. The absence of anger is offered as an observation with plausible explanations attached, not as a finding with data behind it. That is the honest state of it: a group of global policy leaders, writing in a peer-reviewed journal, saying out loud that the arithmetic of coverage has been contested in committee rooms rather than in public, and admitting they do not fully know why.